The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Flossing at least once a week may lower the risk of stroke and atrial fibrillation, according to preliminary results from a ...

Apixaban significantly reduces stroke risk in people with subclinical atrial fibrillation and prior stroke history.

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to stroke and systemic embolism. Vitamin K antagonists have been the only available oral anticoagulants for ...

In February 2024, Corewell Health introduced pulsed field ablation, a treatment procedure significantly safer than previous AFib treatments, at several of its Michigan hospitals. PFA applies a ...

People who regularly floss their teeth (one or more times per week) may lower their risk of stroke caused by a blood clot traveling from the heart and a stroke associated with an irregular heartbeat ...

Something her doctor Wanted to help her avoid, while still protecting her from a stroke. Dr. Steven Filby says atrial fibrillation, or AFib, represents sort of an electrical storm in the heart and ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...

Atrial fibrillation is the most common sustained ... and net clinical outcomes combining bleeding, stroke, embolism, and mortality. The study monitored patients for a median of 2.1 years ...